Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Foreskin keratinocyte (neonatal) refers to cultured epidermal cells derived from the foreskins of newborn males. These cells are used as a cell therapy to accelerate wound closure and healing, particularly in chronic wounds and burns. The product is classified as a biologic and is used in cell transplant therapies. Foreskin keratinocytes form the main component of the skin's outer layer and play a critical role in barrier function and tissue repair. They are often delivered on a matrix such as bovine collagen or type I collagen sponge for application to wounds. Products like Gintuit utilize these cells for regenerative purposes, while similar products such as Apligraf combine them with fibroblasts for enhanced wound healing effects[1][5]. The mechanism involves providing living allogeneic skin cells that promote re-epithelialization, secrete growth factors, and support host tissue regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Foreskin keratinocyte (neonatal).